HF-Related Hospitalization and Readmissions

Slides:



Advertisements
Similar presentations
Effect of Rapid Clinic Follow-Up After Hospital Discharge on 30- Day Heart Failure Readmission Lee Arcement, MD, MPH Dragana Lovre, MD.
Advertisements

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Overview of the 2011 Food and Drug Administration.
Upfront Combination Therapy vs Step-Up Approach for PAH:
Symptom Control and Enhancing Functioning in Schizophrenia
CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.
CLINICAL DILEMMAS IN HEART FAILURE:
Emerging Concepts in Heart Failure
Hospitalizations and Healthcare Costs Need for Reduction in Hospitalizations of Patients With HF
Demystifying Idiopathic Pulmonary Fibrosis
Acute Heart Failure.
Heart Failure and Hospital Readmissions
Heart Rate, HF Admissions, and Readmissions
A CASE CHALLENGE IN HFrEF:
Cardiac Biomarkers.
Renal and Extrarenal Complications of ADPKD: Facilitating Better Patient Care.
Biomarkers in Heart Failure
Select Topics in Cardiovascular Medicine
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
Treatment of Complicated Intra-abdominal Infections
It’s Elementary.
SGLT2 Inhibitors in the Modern Era: Why and Where?
Activity Goals. Activity Goals Discussion Topics.
Cost Effectiveness and Optimal Outcomes in HF
Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.
Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy
nAMD: Switching Therapies - what you need to know
Heart Failure Prevention: Mission Impossible?
Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?
When Would You Use Single Inhaler Triple Therapy in COPD?
What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?
Treating Vasodilatory Shock in the ICU
ADA/EASD Position Statement: Approach to Hyperglycemia Management
A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.
OptiLink HF Trial design: Patients with heart failure who underwent implantation of an ICD were randomized to telemonitoring (n = 505) vs. usual care (n.
Preventing Heart Failure Readmission and Progression
Biomarker-Guided HF Therapy: Is It Cost-Effective?
The Heart Failure Team Heart Failure Care Map First 24 hours.
Evaluating New Therapies in HF
Observational Studies vs. Randomized Controlled Trials (RCT)
Using Heart Rate as a Biomarker in Clinical Practice.
Learning Objectives CMS Measures in HF: 30-day Hospital Readmission Rates.
Updates in Heart Failure:
Revisiting the Pharmacoeconomics of HF
Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy
The Road to Quality Improvement in HER2-Positive Breast Cancer
Modern Advances in Glucose Monitoring
When Is Intrathecal Drug Delivery Appropriate?
New Strategies to Reduce HF Readmissions
Impedence-guided management
Iron Deficiency in Heart Failure
Maximizing Organ Protection in Patients With CKD and Comorbidities on RAAS Therapy.
Improving Adherence to Antiplatelet Therapy After an ACS Event
CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.
Assessing the Burden of Hyperkalemia
When Is Intrathecal Drug Delivery Appropriate?
Clinical Challenges in the Patient With Relapsed Multiple Myeloma
Assessing the Burden of Hyperkalemia
AHF Epidemiology Readmissions Reduction Program.
Championing Evidence-Based Care in Patients With Acute Low Back Pain
Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.
MS, Age, and Immune Function
Pulmonary Arterial Hypertension and Hospitalizations
In-Hospital Treatment for Heart Failure: New Approaches and a Renewed Sense of Hope?
Kevin R. King et al. BTS 2016;1:73-86
My PAH Patient.
Key Data on Improving Outcomes in HF Patients
Case Study #1. Management of Heart Failure With Comorbidities: Challenging Cases for the Cardiologist.
The Power of As-Treated Analyses
What's New in NOACs in AF?.
Presentation transcript:

HF-Related Hospitalization and Readmissions

Epidemiology

Neprilysin Inhibition A New Paradigm for HF Care?

HFpEF

Congestion Drives HF Progression

Gradual Rise in Filling Pressures Before Hospitalization, Whatever the EF

Mainstay Treatment for HF Congestion

Challenge in Monitoring Patients With HF

Short-term Weight Changes Are Informative

CHAMPION Trial The Effect of Pulmonary Artery Pressure-Guided Therapy on HF Hospitalizations vs Standard of Care

Patient Management Database

Hypothesis of the CHAMPION Trial

Main Choices of Intervention

Reduction in Hospitalizations Over Full Duration of Randomized Study

PA Pressure-Guided Therapy Benefits Patients With Common HF Comorbidities

Impact of PA Pressure-Guided HF Management on All-Cause Mortality in GDMT Population

CHAMPION Clinical Trial Substantial Reduction in 30-Day Readmissions in Medicare-Eligible Patients

PA Pressure-Guided HF Management Reduces Hospitalizations in CRT/ICD Population

PA Pressure-Guided HF Management Reduces All-Cause Mortality in CRT/ICD Population

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)